{
  "id": 3014256,
  "title": "Japan approves Rhythm’s Imcivree for hypothalamic obesity",
  "url": "https://urgent.news/2026/08/24/japan-approves-rhythms-imcivree-for-hypothalamic-obesity",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-24T12:12:34.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/japan-approves-rhythms-imcivree-for-hypothalamic-obesity-93CH-4873433"
  },
  "original_language": "en",
  "account": "Japan's Ministry of Health, Labour and Welfare has approved Rhythm Pharmaceuticals' Imcivree for the treatment of acquired hypothalamic obesity, the first therapy authorized in the country for this rare disease. Acquired hypothalamic obesity, marked by rapid weight gain following hypothalamus damage, affects an estimated 5,000 to 8,000 people in Japan. The approval stems from data from the Phase 3 TRANSCEND trial, which included 142 patients, including 12 Japanese and 10 supplemental participants. Imcivree, a melanocortin-4 receptor agonist, showed an 18.8% reduction in BMI compared to placebo. The drug is already approved in the U.S. and EU for similar uses and is currently being prepared for launch in Japan by the end of 2026, pending final pricing.",
  "summary": null,
  "key_points": [
    "Japan's Ministry of Health approves Imcivree for acquired hypothalamic obesity",
    "Imcivree, a melanocortin-4 receptor agonist, reduces BMI by 18.8% in trials",
    "Imcivree to be launched in Japan by end of 2026"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}